IGM Biosciences(IGMS) - 2024 Q4 - Annual Results

Strategic Updates and Restructuring - The company announced a strategic update to halt further development of imvotamab and IGM-2644, resulting in an approximately 73% reduction in force to preserve cash[6] - The company is unable to estimate the costs and charges associated with the 2025 Restructuring at this time and will file an amendment once determined[7] Evaluation of Strategic Alternatives - The company is evaluating internal options and potential strategic alternatives to maximize shareholder value[8]